Antonia Lepida1, Astrid Marot2, Eric Trépo1,3, Delphine Degré1, Christophe Moreno1,3, Pierre Deltenre1,4. 1. Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium. 2. Department of Gastroenterology and Hepatology, CHU UCL Namur, Université Catholique de Louvain, Yvoir, Belgium. 3. Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Brussels, Belgium. 4. Department of Gastroenterology and Hepatology, Clinique St Luc, Bouge, Belgium.
Abstract
BACKGROUND: Few effective treatments are available for patients with cirrhosis and refractory ascites. New treatment modalities are needed for these patients. AIM: To synthesise the available evidence on the efficacy and safety of automated low-flow ascites pump therapy in patients with cirrhosis and refractory ascites. METHODS: Electronic databases were searched for trials evaluating automated low-flow ascites pump therapy in patients with refractory ascites. RESULTS: Nine studies were included. Eight were case series, one was a randomised controlled trial. Pooled estimate rates were 0.62 (95% CI = 0.49-0.74) for the absence of requirement of large volume paracentesis (LVP) after pump insertion, 0.30 (95% CI = 0.17-0.47) for acute kidney injury, 0.27 (95% CI = 0.13-0.49) for bacterial peritonitis and 0.20 (95% CI = 0.09-0.37) for urinary tract infection. There was high heterogeneity between studies which was often reduced or eliminated in sensitivity analyses by excluding studies of patients with a mean or median model for end-stage liver disease (MELD) score > 15. Results of sensitivity analyses were similar to those of overall analyses. Mean increase in serum creatinine level after pump insertion was 23 µmol/L (95% CI = 10-35) with no heterogeneity between studies. The pooled estimate rate for pump-related side effects was 0.77 (95% CI = 0.64-0.87) with low heterogeneity between studies. CONCLUSION: This meta-analysis demonstrates that most patients treated with automated low-flow ascites pump therapy do not require LVP after pump insertion. Acute kidney injury occurs in 30% of patients and creatinine levels increase by a mean of 23 µmol/L after pump insertion. Bacterial peritonitis and urinary tract infection occur in 27% and 20% of patients respectively.
BACKGROUND: Few effective treatments are available for patients with cirrhosis and refractory ascites. New treatment modalities are needed for these patients. AIM: To synthesise the available evidence on the efficacy and safety of automated low-flow ascites pump therapy in patients with cirrhosis and refractory ascites. METHODS: Electronic databases were searched for trials evaluating automated low-flow ascites pump therapy in patients with refractory ascites. RESULTS: Nine studies were included. Eight were case series, one was a randomised controlled trial. Pooled estimate rates were 0.62 (95% CI = 0.49-0.74) for the absence of requirement of large volume paracentesis (LVP) after pump insertion, 0.30 (95% CI = 0.17-0.47) for acute kidney injury, 0.27 (95% CI = 0.13-0.49) for bacterial peritonitis and 0.20 (95% CI = 0.09-0.37) for urinary tract infection. There was high heterogeneity between studies which was often reduced or eliminated in sensitivity analyses by excluding studies of patients with a mean or median model for end-stage liver disease (MELD) score > 15. Results of sensitivity analyses were similar to those of overall analyses. Mean increase in serum creatinine level after pump insertion was 23 µmol/L (95% CI = 10-35) with no heterogeneity between studies. The pooled estimate rate for pump-related side effects was 0.77 (95% CI = 0.64-0.87) with low heterogeneity between studies. CONCLUSION: This meta-analysis demonstrates that most patients treated with automated low-flow ascites pump therapy do not require LVP after pump insertion. Acute kidney injury occurs in 30% of patients and creatinine levels increase by a mean of 23 µmol/L after pump insertion. Bacterial peritonitis and urinary tract infection occur in 27% and 20% of patients respectively.
Authors: Valerie Will; Susana G Rodrigues; Guido Stirnimann; Andrea De Gottardi; Jaime Bosch; Annalisa Berzigotti Journal: United European Gastroenterol J Date: 2020-06-26 Impact factor: 4.623
Authors: Guruprasad P Aithal; Naaventhan Palaniyappan; Louise China; Suvi Härmälä; Lucia Macken; Jennifer M Ryan; Emilie A Wilkes; Kevin Moore; Joanna A Leithead; Peter C Hayes; Alastair J O'Brien; Sumita Verma Journal: Gut Date: 2020-10-16 Impact factor: 23.059
Authors: Niels Kristian Aagaard; Massimo Malago; Andrea De Gottardi; Michael Thomas; Gerd Sauter; Cornelius Engelmann; David Aranovich; Michal Cohen; Thierry Thévenot; Thomas Ehmann; Jeroen Capel; Paolo Angeli; Rajiv Jalan; Guido Stirnimann Journal: BMC Gastroenterol Date: 2022-03-08 Impact factor: 3.067
Authors: Delphine Weil-Verhoeven; Vincent Di Martino; Guido Stirnimann; Jean Paul Cervoni; Eric Nguyen-Khac; Thierry Thévenot Journal: World J Hepatol Date: 2022-07-27
Authors: Guido Stirnimann; Thomas Berg; Laurent Spahr; Stefan Zeuzem; Stuart McPherson; Frank Lammert; Federico Storni; Vanessa Banz; Jana Babatz; Victor Vargas; Andreas Geier; Cornelius Engelmann; Adam Herber; Claudia Trepte; Jeroen Capel; Andrea De Gottardi Journal: Liver Int Date: 2022-07-25 Impact factor: 8.754